The very early response predict prognosis in active axial spondyloarthritis patients treated with tumor necrosis factor(TNF)-a blocker

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPB-17013924

Enrollment

Unknown

Registered

2017-12-14

Start date

2015-01-01

Completion date

Unknown

Last updated

2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

axial spondyloarthritis

Interventions

Case series:etanercept

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: The patients who fulfilled the ASAS classification criteria for axial spondyloarthritis were included. The disease had failed to respond to initial therapy with sulfasalazine or methotrexate in all patients, and all patients displayed moderate to highly active AS as defined by a ASDAS of =2.1 or BASDAI=4.

Exclusion criteria

Exclusion criteria: the patients who used to accept biologic therapy 6 month before this study were excluded.

Design outcomes

Primary

Measure	Time frame
ASDAS;	—

Countries

China

Contacts

Public ContactLiyang Gu

Ren Ji Hospital South Campus, Shanghai Jiaotong University School of Medicine

emma-gly@163.com+86 13816445677

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026